Based on the BridgeBio Pharma Inc stock forecast from 11 analysts, the average analyst target price for BridgeBio Pharma Inc is USD 51.84 over the next 12 months. BridgeBio Pharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BridgeBio Pharma Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, BridgeBio Pharma Inc’s stock price was USD 31.40. BridgeBio Pharma Inc’s stock price has changed by -4.88% over the past week, -1.13% over the past month and +8.35% over the last year.
No recent analyst target price found for BridgeBio Pharma Inc
No recent average analyst rating found for BridgeBio Pharma Inc
Company Overview BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California. Read Less
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete T...Read More
Frequently Asked Questions About BridgeBio Pharma Inc (BBIO) Stock
Based on ratings from 11 analysts BridgeBio Pharma Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 23 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on BBIO's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for BBIO is USD 51.84 over the next 12 months. The maximum analyst target price is USD 95 while the minimum anlayst target price is USD 37.
Unfortunately we do not have enough data on BBIO's stock to indicate if its overvalued.
The last closing price of BBIO's stock was USD 31.40.
The most recent market capitalization for BBIO is USD 6.00B.
Based on targets from 11 analysts, the average taret price for BBIO is projected at USD 51.84 over the next 12 months.
This means that BBIO's stock price may go up by +65.10% over the next 12 months.
We can't find any ETFs which contains BridgeBio Pharma Inc's stock.
As per our most recent records BridgeBio Pharma Inc has 725 Employees.
BridgeBio Pharma Inc's registered address is 3160 Porter Drive, Palo Alto, CA, United States, 94304.
You can get more information about it from BridgeBio Pharma Inc's website at https://bridgebio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About BridgeBio Pharma Inc (BBIO) Stock
Based on ratings from 11 analysts BridgeBio Pharma Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 23 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on BBIO's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for BBIO is USD 51.84 over the next 12 months. The maximum analyst target price is USD 95 while the minimum anlayst target price is USD 37.
Unfortunately we do not have enough data on BBIO's stock to indicate if its overvalued.
The last closing price of BBIO's stock was USD 31.40.
The most recent market capitalization for BBIO is USD 6.00B.
Based on targets from 11 analysts, the average taret price for BBIO is projected at USD 51.84 over the next 12 months.
This means that BBIO's stock price may go up by +65.10% over the next 12 months.
We can't find any ETFs which contains BridgeBio Pharma Inc's stock.
As per our most recent records BridgeBio Pharma Inc has 725 Employees.
BridgeBio Pharma Inc's registered address is 3160 Porter Drive, Palo Alto, CA, United States, 94304.
You can get more information about it from BridgeBio Pharma Inc's website at https://bridgebio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BBIO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
